Home › NDC Lookup › RxCUI directory › RxCUI 2054266

{14 (migalastat 123 MG Oral Capsule) } Pack — RxCUI 2054266

RxNorm drug concept · Generic pack
RxCUI 2054266 Generic pack · GPCK ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2054266
Official name{14 (migalastat 123 MG Oral Capsule) } Pack
Concept typeGeneric pack (GPCK)
RxNorm statusCurrent RxNorm concept
Also known as{14 (migalastat 123 MG (as migalastat HCl 150 MG) Oral Capsule)} Pack; migALAstat 123 MG 28 Day (4 Week) Wallet Pack
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)47 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How {14 (migalastat 123 MG Oral Capsule) } Pack Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {14 (migalastat 123 MG Oral Capsule) } Pack RxCUI 2054266

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Migalastat 2054252
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Galafold 2054258
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Migalastat Oral Capsule 2054256
    • Migalastat Oral Product 2054254
    • Migalastat Pill 2054255
    • Migalastat Oral Capsule [Galafold] 2054260
    • Galafold Oral Product 2054261
    • Galafold Pill 2054262
    • Pack 746839
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 15 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Migalastat 123 MG Oral Capsule SCD · 2054257
  • Migalastat 123 MG SCDC · 2054253
  • Migalastat Oral Capsule SCDF · 2054256
  • Migalastat Oral Product SCDG · 2054254
  • Migalastat Pill SCDG · 2054255

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2054266 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
71904-0100-01 14 BLISTER PACK in 1 CARTON (71904-100-01) / 1 CAPSULE in 1... Galafold Amicus Therapeutics US, LLC 2018-08-10
Observed labelers: Amicus Therapeutics US, LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.